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Abstract 1 
Intracellular adhesion molecule-1 (ICAM-1) is a transmembrane glycoprotein expressed on 2 
the cell surface of numerous cell types such as endothelial and epithelial cells, vascular 3 
smooth muscle cells and certain leukocyte sub-sets. With respect to the latter, ICAM-1 has 4 
been detected on neutrophils in several clinical and experimental settings but little is known 5 
about the regulation of expression or function of neutrophil ICAM-1. In this study we report 6 
on the de-novo induction of ICAM-1 on the cell surface of murine neutrophils by 7 
lipopolysaccharide (LPS), TNF and zymosan particles in vitro. The induction of neutrophil 8 
ICAM-1 was associated with enhanced phagocytosis of zymosan particles and ROS 9 
generation. Conversely, neutrophils from ICAM-1 deficient mice were defective in these 10 
effector functions. Mechanistically, ICAM-1-mediated intracellular signalling appeared to 11 
support neutrophil ROS generation and phagocytosis. In vivo, LPS-induced inflammation in 12 
the mouse cremaster muscle and peritoneal cavity led to ICAM-1 expression on 13 
intravascular and locally transmigrated neutrophils. The use of chimeric mice deficient in 14 
ICAM-1 on myeloid cells demonstrated that neutrophil ICAM-1 was not required for local 15 
neutrophil transmigration but supported optimal intravascular and extravascular 16 
phagocytosis of zymosan particles. Collectively the present results shed light on regulation 17 
of expression and function of ICAM-1 on neutrophils and identify it as an additional regulator 18 
of neutrophil effector responses in host defence.  19 
  20 
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Introduction 1 
ICAM-1 (CD54) is a member of the immunoglobulin (Ig)-like gene superfamily composed of 2 
an extracellular domain containing 5 Ig-like structures, a transmembrane domain and a short 3 
cytoplasmic tail of 28 amino acids.1-3 It is a key adhesion molecule with significant signalling 4 
properties that has been associated with numerous cellular responses such as cell 5 
adhesion, migration and aggregation.4-6 ICAM-1 is constitutively expressed on the surface of 6 
a wide range of cells including endothelial and epithelial cells, smooth muscle cells, 7 
pericytes, fibroblasts and keratinocytes.4;5;7-9 The expression of ICAM-1 is primarily regulated 8 
in a transcriptional manner, notably by inflammatory stimuli such as the cytokines IL-1β and 9 
TNF and by LPS.4;9;10 For example, these stimuli can enhance the constitutive expression of 10 
endothelial cell ICAM-1 and promote leukocyte-endothelial cell adhesion and trafficking via 11 
interactions of ICAM-1 with its key leukocyte ligands, the integrins LFA-1 and Mac-1.8;11;12 12 
Ligation of endothelial cell ICAM-1 can trigger elevations in cytoplasmic Ca2+, activation of 13 
myosin contractility, PKC and of the small GTPases (e.g. Rho, Rac and Rap1).6;10 A number 14 
of cytosolic and adaptor proteins, such as α-actinins, ezrin, cortactin and filamin B, also 15 
interact with the C-terminal domain of endothelial cell ICAM-1 and contribute to localised 16 
cytoskeletal re-arrangements and leukocyte-endothelial  interactions.13 How such events are 17 
linked in endothelial cells, and details of ICAM-1 signalling in different cell types are not fully 18 
understood, but it is generally accepted that the cytoplasmic tail of the molecule plays a key 19 
role in supporting ICAM-1-mediated responses.  20 
In addition to being expressed on tissue-resident cells, ICAM-1 is expressed on most 21 
leukocyte sub-sets such as activated lymphocytes and monocytes. The best documented 22 
role of leukocyte ICAM-1 is in the formation of immune synapses between T-cells and 23 
antigen presenting or NK cells and their targets.14 These responses are primarily mediated 24 
by ICAM-1-LFA-1 interactions.14 With respect to neutrophils, ICAM-1 is generally absent or 25 
expressed at very low levels on circulating blood cells in humans and mice15-18 though 26 
elevated levels have been reported in a limited number of clinical and experimental 27 
scenarios. For example, ICAM-1 has been detected on blood and peritoneal neutrophils in 28 
patients with bacterial peritonitis,19 on blood and nasopharyngeal aspirated neutrophils in 29 
infants with respiratory syncytial virus,20 on blood neutrophils post low dose intravenous (i.v.) 30 
endotoxin21 and on blood and bronchoalveolar lavage neutrophils from septic and 31 
sarcoidosis patients.22 In animal models, immunisation of mice with P. aeruginosa  can also 32 
upregulate neutrophil ICAM-1 in vivo18 and neutrophil reverse transendothelial cell migration 33 
has been associated with increased neutrophil ICAM-1 expression in vitro and in vivo with 34 
respect to human and mouse neutrophils.17;23 Furthermore, there are indications that G-CSF, 35 
GM-CSF, LPS, TNF, bacterial lipoprotein and S. aureus can induce expression of ICAM-1 on 36 
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human neutrophils in vitro.16;24-27 In terms of its physiological role, neutrophil ICAM-1 has 1 
been linked to cellular aggregation, increased generation of reactive oxygen species 2 
(ROS)26;28 and in supporting interactions with other components of the immune system.21 3 
Despite the above scant reports, little is known about the mechanisms through which ICAM-4 
1 is expressed on neutrophils and its potential pathophysiological functions. In the present 5 
study we demonstrate the ability of murine neutrophils to upregulate ICAM-1 in a stimulus-6 
specific manner both in vitro and in vivo with LPS being identified as an effective inducer of 7 
neutrophil ICAM-1 mRNA. Functionally, neutrophil ICAM-1 was found to be important for 8 
enhanced neutrophil effector functions, with ICAM-1 deficient neutrophils exhibiting 9 
significantly reduced levels of phagocytosis in vitro and in murine models of endotoxemia. 10 
The mechanism through which neutrophil ICAM-1 mediated phagocytosis appeared to be 11 
linked to ICAM-1-fibrinogen interactions and ICAM-1-mediated intracellular signalling 12 
involving the tyrosine kinase Syk. Collectively, the present findings shed significant light on 13 
the regulation and function of neutrophil ICAM-1 and suggest that in addition to its 14 
expression on endothelial cells and lymphocytes, neutrophil ICAM-1 contributes to the host’s 15 
defence mechanism against pathogens. 16 
 17 
 18 
Materials and Methods 19 
For detailed methodology see Supplementary Materials. 20 
Animals: Male wild type (WT), ICAM-1 deficient (KO),29 or heterozygous LysM-eGFP mice 21 
on a C57BL/6 background were used. LysM-eGFP30 mice are referred to as WT-LysM-22 
eGFP, to distinguish them from WT mice. All experiments were performed under the UK 23 
Home Office legislation for the protection of animals. 24 
Generation of chimeric mice: A mixture of WT-LysM-eGFP and ICAM-1 KO bone marrow 25 
was injected intravenously (i.v.) to irradiated WT mice to create chimeric mice that 26 
expressed ICAM-1 on the vasculature with ICAM-1 KO or WT-LysM-GFP leukocytes.31  27 
In vivo inflammatory models:  Animals were injected with intrascrotal (i.s.) or intraperitoneal 28 
(i.p.) LPS or IL-1β and after 4 hrs blood, peritoneal lavage and tissue samples were 29 
collected. In some cases, fluorescent zymosan-Texas-Red (ZymTR) was injected (i.p. or i.v.) 30 
15 minutes prior to tissue collection to quantify in vivo phagocytosis. Cremaster muscles and 31 
lungs were labelled with fluorescent mAbs against PECAM-1 (endothelial cell junctions), 32 
S100a9 (neutrophils), lectin (vasculature) and ICAM-1, and analysed by confocal 33 
microscopy. Leukocytes from blood, enzymatically digested lung tissue or peritoneal lavage 34 
were analysed by flow cytometry (see below). 35 
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Quantification of ROS and phagocytosis: Whole blood from WT or ICAM-1 KO mice was 1 
stimulated with a panel of inflammatory mediators for 4 hrs. The ROS probe 2 
dihydrorhodamine-123 (DHR), ZymTR and all pharmacological interventions were added to 3 
blood samples as detailed.  4 
Flow Cytometry: Blood, peritoneal lavage or lung tissue digest leukocytes were labelled with 5 
the fluorescent dead cell nuclear marker DAPI and fluorescent mAbs against CD45, Ly6G, 6 
ICAM-1, or isotype controls, or the ROS probe DHR or ZymTR prior to analysis by flow 7 
cytometry.  8 
Confocal microscopy: Fluorescently labelled cremaster muscles, lung tissues or isolated 9 
leukocytes were viewed using a Leica-SP5 confocal microscope incorporating a 20× water-10 
dipping objective (NA 1.0). Quantifications were carried out using Imaris (Bitplane) or Leica 11 
LASF-Lite software.  12 
Quantitative RT-PCR: Neutrophils were purified by FACS. The fold change in ICAM-1 mRNA 13 
was quantified using GAPDH as a housekeeping gene. 14 
Western Blot: Naïve or LPS stimulated neutrophils were purified and treated with protease 15 
inhibitor before lysis. ICAM-1 and β-actin expression was detected by Western Blot. 16 
Statistical analysis: Results are presented as mean ± s.e.m. Statistical significance was 17 
assessed by the Student t-test or by one-way analysis of variance (ANOVA) with Newman-18 
Keuls multiple comparison test. P values below 0.05 were considered significant. 19 
 20 
 21 
Results  22 
ICAM-1 is upregulated on mouse neutrophils in a stimulus-specific manner in vitro 23 
Whilst a number of studies have reported on the presence of ICAM-1 on neutrophils,19;20;22 24 
little is known about the regulation of this expression. Analysis of mouse blood leukocytes by 25 
flow cytometry indicated a low percentage of ICAM-1 positive neutrophils. This was not 26 
changed following in vitro stimulation of whole blood with a number of neutrophil chemotactic 27 
stimuli (LTB4, KC and fMLP) or with the cytokine IL-1β (4 hrs stimulation at 37°C for all 28 
mediators; Fig 1A). In contrast, LPS, TNF and zymosan particles significantly increased the 29 
percentage of ICAM-1 expressing neutrophils (Fig 1A). The lack of ICAM-1 staining in 30 
samples from ICAM-1 KO mice confirmed the labelling specificity. Of note, WT and ICAM-1 31 
KO neutrophils showed similar levels of enhanced CD18 expression in response to LPS 32 
(data not shown).  33 
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The effect of LPS was investigated further and shown to induce ICAM-1 on neutrophils in 1 
terms of relative fluorescence intensity (RFI) and also in a dose-dependent manner (Figs 1B 2 
and 1C). LPS-induced expression of ICAM-1 on neutrophils was time-dependent and a 3 
significant effect was noted at 3 hrs post stimulation (Fig 1D). The observed slow expression 4 
suggested that this ICAM-1 was not derived from preformed intracellular stores and indeed 5 
no evidence for intracellular expression of ICAM-1 in permeablised unstimulated neutrophils 6 
was observed (Fig 1E). Quantitative RT-PCR analysis of unstimulated and LPS-stimulated 7 
purified neutrophils indicated low levels of ICAM-1 mRNA in unstimulated cells that was 8 
significantly elevated by LPS, providing evidence for de novo generation of ICAM-1 (Fig 1F). 9 
Western Blot analysis of unstimulated and LPS-stimulated neutrophils, treated with a 10 
protease inhibitor, confirmed that naïve cells have low or absent levels of ICAM-1 (Fig 1G). 11 
Collectively these results demonstrate that murine neutrophils can be stimulated to express 12 
cell surface ICAM-1 in a stimulus-specific manner via induction of ICAM-1 mRNA and de 13 
novo generation of ICAM-1 protein.  14 
 15 
Neutrophil ICAM-1 expression facilitates enhanced neutrophil effector functions 16 
The potential functional implications of LPS-induced neutrophil ICAM-1 were next 17 
investigated. As the ICAM-1 ligand Mac-1 is a key regulator of neutrophil phagocytosis, we 18 
hypothesised that neutrophil ICAM-1 might also facilitate this process. To address this 19 
possibility neutrophil phagocytosis was quantified using fluorescent zymosan particles 20 
(ZymTR). LPS stimulation of WT blood samples significantly increased the percentage of 21 
ZymTR positive neutrophils (ZymTRpos), as compared to saline-treated samples (Fig 2A and 22 
B). This response was significantly suppressed in samples from ICAM-1 KOs (Fig 2B). Use 23 
of an ImageStream platform, combining fluorescence microscopy with high-throughput flow 24 
cytometry, indicated that in both genotypes the majority of ZymTR-associated neutrophils 25 
had internalised the ZymTR particles within 15 minutes (ie ~97%), confirming that this assay 26 
quantifies phagocytosis of ZymTR, rather than surface decoration. Neutrophil ICAM-1 also 27 
appeared to support ROS generation. Specifically, LPS-stimulated WT samples showed 28 
significantly higher DHR signal, as compared to saline-treated samples, and this was 29 
significantly reduced in samples from ICAM-1 KO mice (Fig 2C). Furthermore, ICAM-1 30 
positive neutrophils exhibited a greater DHR signal than ICAM-1 negative cells (Fig 2D). 31 
Interestingly, across the panel of neutrophil stimuli used in Fig 1A a correlation between 32 
ICAM-1 upregulation and ROS generation was noted with LPS and TNF inducing ICAM-1 33 
expression and ROS generation, while IL-1β, fMLP and KC did not (Fig 2E). Collectively, 34 
these results demonstrate the involvement of neutrophil ICAM-1 in generation of intracellular 35 
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ROS and report on a previously unknown function of neutrophil ICAM-1 as a facilitator of 1 
phagocytosis.   2 
 3 
Mechanism of neutrophil ICAM-1-mediated enhanced effector function? 4 
Having identified a role for neutrophil ICAM-1 in phagocytosis and ROS generation, the 5 
potential associated mechanisms were addressed. To test the hypothesis that cell surface 6 
ICAM-1 may be involved in uptake of zymosan particles the effect of an anti-ICAM-1 mAb 7 
that inhibits ICAM-1 integrin binding32;33 on LPS-induced phagocytosis was examined. In 8 
contrast to the effects seen under conditions of ICAM-1 genetic deletion (Fig 2B), surface 9 
blockade of ICAM-1 had no impact on zymosan phagocytosis (Fig 3A). Using the same 10 
protocol, as expected an anti-Mac-1 mAb significantly inhibited LPS-induced zymosan 11 
phagocytosis with a similar level of suppression in both WT and ICAM-1 KO samples. As no 12 
role for ICAM-1-integrin binding was seen, we hypothesised that neutrophil ICAM-1 may 13 
interact with the other important ICAM-1 ligand fibrinogen and hence support uptake of 14 
fibrinogen-coated zymosan particles. To test this possibility, we employed a peptide 15 
mimicking the gamma domain of fibrinogen that competitively inhibits ICAM-1-fibrinogen 16 
interactions34;35. Addition of this peptide to LPS-stimulated WT samples led to a small but 17 
significant inhibition of ZymTR phagocytosis (Fig 3B). Importantly, the peptide blocker had 18 
no effect on phagocytosis by LPS-stimulated ICAM-1 KO neutrophils (Fig 3B), indicating the 19 
specificity of the inhibitor for ICAM-1-mediated responses.      20 
Since cell surface binding capability of neutrophil ICAM-1 revealed a modest role in 21 
regulation of phagocytosis, we hypothesised that the principal role of neutrophil ICAM-1 in 22 
regulating neutrophil effector functions may reside in its signalling capability. To test this, the 23 
effect of a cell permeant peptide that mimics the intracellular C-terminal domain of ICAM-1, 24 
widely used as a blocker of ICAM-1-mediated intracellular signalling,36;37 was investigated. 25 
Pre-treatment of WT blood samples with the peptide led to significant inhibition of LPS-26 
induced phagocytosis of zymosan particles (Fig 3C). Importantly, the peptide had no effect 27 
on phagocytosis responses detected in ICAM-1 KO samples (Fig 3C), indicating specificity 28 
of the peptide for ICAM-1-mediated events. 29 
As the cytoplasmic tyrosine kinase Syk has been linked to both ICAM-1 intracellular 30 
signalling38 and phagocytosis,39;40 the potential role of this kinase in LPS-induced 31 
phagocytosis was investigated using the inhibitor Piceatannol. Pre-treatment of blood 32 
samples with Piceatannol dose-dependently inhibited LPS-induced ZymTR uptake in WT 33 
neutrophils. ICAM-1 KO neutrophils were less sensitive to Piceatannol, indicating that Syk 34 
mediated mechanisms have an ICAM-1 dependent component (Fig 3D). Furthermore, 35 
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antibody cross-linking of ICAM-1 that is known to activate intracellular signalling,10 enhanced 1 
LPS-stimulated ROS generation (Fig 3E), providing additional indication for the involvement 2 
of ICAM-1-signalling in regulation of neutrophil effector functions.  3 
Collectively these data provide evidence to suggest that ICAM-1 expression enhances 4 
neutrophil effector functions via interactions with fibrinogen and through intracellular 5 
signalling involving activation of Syk mediated pathways. 6 
 7 
ICAM-1 is expressed on neutrophils in models of endotoxemia in vivo 8 
Having found that LPS induces surface expression of ICAM-1 on neutrophils and that this 9 
expression supports enhanced neutrophil effector functions in vitro, we next sought to 10 
investigate the expression and potential functions of neutrophil ICAM-1 in vivo. For this 11 
purpose, two murine models of local endotoxemia, namely LPS-stimulated cremaster 12 
muscles (i.s.) and LPS-induced peritonitis (i.p.), were employed. For comparison, the same 13 
models, as driven by locally injected IL-1β, a stimulus that did not induce neutrophil ICAM-1 14 
expression in vitro (Fig 1A), were also investigated. Locally injected LPS and IL-1β induced 15 
significant neutrophil infiltration in the cremaster muscle and peritoneal cavity (Fig 4A-C). 16 
Furthermore, in both models, LPS-induced tissue infiltrated neutrophils exhibited significant 17 
expression of ICAM-1 (Fig 4D-F). Of note, neutrophils accumulating in response to locally 18 
injected IL-1β showed very little or no ICAM-1 expression (Figs 4C-D). In both models, local 19 
LPS (but not IL-1β) appeared to exert a systemic effect in that there was a significant 20 
increase in the proportion of neutrophils in blood and in enzymatically digested lung tissues 21 
(Fig 4G). Importantly, i.v. administration of a fluorescently-labelled anti-Ly6G antibody (used 22 
to label all intravascular neutrophils) prior to tissue collection, indicated that in both naïve 23 
and LPS treated animals >90% of neutrophils in the lung digest were intravascular. As found 24 
with the tissue infiltrated cells, in the LPS-driven reactions (but not IL-1β), an increase in the 25 
percentage of blood ICAM-1 positive neutrophils was detected (Fig 4H). Lung intravascular 26 
neutrophils also exhibited increased ICAM-1 expression following intraperitoneal LPS (data 27 
not shown).   28 
Collectively these results demonstrate that vascular and tissue infiltrated neutrophils can 29 
express ICAM-1 on their cell surface in a stimulus-dependent manner.  30 
 31 
Neutrophil ICAM-1 does not support neutrophil transmigration in vivo  32 
To investigate the functional role of neutrophil ICAM-1 in vivo we generated chimeric mice 33 
expressing ICAM-1 on their vasculature but deficient in neutrophil ICAM-1. Lethally irradiated 34 
WT mice were reconstituted with a mixture of WT bone-marrow hematopoietic cells from 35 
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LysM-eGFP Ki mice (express GFP-labelled myeloid cells) and GFP negative ICAM-1 KO 1 
mice. There was an average peripheral blood ratio of 60:40 WT:KO neutrophils in these 2 
animals (Supplementary figure 1A). This model provided a valuable tool for directly 3 
investigating the role of neutrophil ICAM-1 in neutrophil transmigration in vivo. In the 4 
cremaster muscle and peritonitis models, LPS-induced local neutrophil infiltration was 5 
quantified by confocal microscopy and flow cytometry, respectively, enabling WT and KO 6 
neutrophils to be easily distinguished in the same samples (i.e. WT neutrophils were double 7 
positive for GFP and S100a9 or Ly6G whilst ICAM-1 KO neutrophils were only S100a9 or 8 
Ly6G positive). With this rigorous approach, the same WT:KO ratio was seen in the 9 
peritoneal cavity as in the peripheral blood (Supplementary figure 1A). When the numbers of 10 
extravasated cells were normalised to the blood ratio of individual animals no significant 11 
difference in tissue infiltration of WT or ICAM-1 KO neutrophils was noted (Fig 5A-C). These 12 
results demonstrate that neutrophil ICAM-1 is not required for acute neutrophil infiltration in 13 
response to local LPS.    14 
 15 
ICAM-1 facilitates neutrophil phagocytosis in vivo  16 
As our in vitro studies identified phagocytosis as a principal effector function associated with 17 
neutrophil ICAM-1, we sought to investigate this association in vivo. For this purpose, we 18 
took advantage of the chimeric mice detailed above. The mice were subjected to LPS-19 
induced peritonitis, a model that induces blood neutrophilia (Fig 4G), tissue infiltration of 20 
neutrophils (Fig 4C) and ICAM-1 expression on intravascular and peritoneal neutrophils (Fig 21 
4G and 4F). ZymTR was given i.v. or i.p. 15 minutes prior to sample and/or tissue collection 22 
and percentage of ZymTRpos WT-LysM-eGFP and ICAM-1 KO neutrophils was quantified by 23 
flow cytometry. This technique enabled us to directly compare WT and ICAM-1 KO 24 
neutrophils in the same samples, over-riding potential animal variations. With this approach, 25 
WT peritoneal neutrophils showed a robust phagocytosis response that was significantly 26 
reduced in ICAM-1 KO cells (Fig 6A).  27 
In contrast, blood neutrophils exhibited a low frequency of ZymTR uptake regardless of 28 
genotype or stimulation (Fig 6B). Interestingly, WT lung digest neutrophils, that represent 29 
predominantly pulmonary vascular neutrophils, showed a marked phagocytosis response in 30 
control animals that was further increased in LPS-stimulated mice (Fig 6B). This suggests 31 
that the slow blood flow of the pulmonary vasculature supports greater contact between 32 
circulating neutrophils and zymosan particles. Lung digest ICAM-1 KO neutrophils showed a 33 
similar level of ZymTRpos neutrophils in saline treated mice, but no increase in phagocytosis 34 
was seen in LPS-stimulated ICAM-1 KO animals (Fig 6B). Analysis of these events in terms 35 
of the total number of ZymTRpos pulmonary vascular neutrophils showed a similar pattern. In 36 
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LPS-stimulated mice the total number of ZymTRpos WT neutrophils increased by 47.9% and 1 
in the same animals no such increase was seen with ICAM-1 KO cells (Fig 6C). Interestingly 2 
there was a small but significant increase in the proportion of WT neutrophils in the lung 3 
tissue digest as compared to blood, suggesting a potential  preferential retention of WT cells 4 
in the lung vasculature. Confocal microscopy images of lung tissue of LPS-stimulated (i.p) 5 
mice illustrate the dense network of small capillaries in lungs and also the notable presence 6 
of luminal ZymTRpos neutrophils (Fig 6D). In contrast, the microvessels of the cremaster are 7 
much less dense, and show little evidence of luminal ZymTR particles in LPS (i.s.) 8 
stimulated tissues (Fig 6D).   9 
Collectively these results indicate that neutrophil ICAM-1 can support enhanced 10 
phagocytosis both within the vascular lumen (most notably in the pulmonary vasculature) 11 
and in the extravascular tissue.  12 
 13 
 14 
Discussion  15 
Despite the tremendous interest in the expression and function of endothelial cell ICAM-1 16 
and the co-stimulatory role of ICAM-1 in lymphocytes, little is known about neutrophil 17 
expressed ICAM-1. In the present study we identify a stimulus-specific transcriptional 18 
regulation of ICAM-1 on murine neutrophils and report on the ability of certain stimuli to 19 
induce neutrophil ICAM-1 both in vitro and in vivo. Functionally, this expression was not 20 
essential for neutrophil migration into sites of inflammation but supported enhanced 21 
neutrophil ROS generation and phagocytosis. The findings shed light on the mechanisms of 22 
expression of neutrophil ICAM-1 and identify it as a novel component of the host’s innate 23 
immune response to pathogens.  24 
ICAM-1 is not commonly considered as a neutrophil cell surface antigen but it has been 25 
detected on neutrophils in numerous infectious and inflammatory clinical settings.19;20;22 Due 26 
to the disparity of reports, a key objective of the present work was to gain a better 27 
understanding of the expression and regulation of expression of neutrophil ICAM-1, as 28 
studied using murine models. Initial in vitro experiments showed that in unstimulated murine 29 
blood  only ~10% of neutrophils were ICAM-1 positive and that these cells expressed very 30 
low levels of the molecule (RFI <2.0). Furthermore, stimulation with a wide-range of 31 
neutrophil activating and/or pro-inflammatory mediators (KC, fMLP, LTB4 and IL-1β) had no 32 
impact on neutrophil ICAM-1 expression. However LPS, TNF and zymosan particles induced 33 
a significant upregulation of ICAM-1 (~60-80% ICAM-1 positive cells), indicating that this 34 
response is stimulus-specific. Of importance, LPS-induced upregulation of ICAM-1 was slow 35 
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(~3 hrs) and associated with induction of ICAM-1 mRNA, suggesting that it is 1 
transcriptionally regulated. This finding is in line with transcriptional regulation of ICAM-1 2 
expression in other cell types such as endothelial and epithelial cells, pericytes and 3 
keratinocytes.4;7;9 Furthermore, it is now well accepted that neutrophils are not 4 
transcriptionally static cells and in fact have the capability of significant de novo protein 5 
synthesis.41;42 Finally, our observed stimulus-specific pattern of murine neutrophil ICAM-1 6 
expression is in agreement with reports that have linked human neutrophil ICAM-1 7 
expression with the stimulants LPS and TNF,21;24;26 bacterial lipoprotein25 and S. aureus24 in 8 
vitro.  9 
As the profile of stimuli that induce neutrophil ICAM-1 are pathogen-derived and/or are 10 
commonly released under conditions of infections, we hypothesised that elevated neutrophil 11 
ICAM-1 may represent a physiological response associated with pathogen clearance. 12 
Indeed, whilst neutrophil ICAM-1 has to date been largely investigated in the context of 13 
neutrophil-neutrophil adhesion, aggregation26;28 and neutrophil interactions with other 14 
components of the immune response,21 here we made the novel observation that neutrophil 15 
ICAM-1 supports an efficient phagocytosis response and is also associated with enhanced 16 
ROS generation. Whilst endothelial and epithelial cell ICAM-1 have been shown to support 17 
neutrophil phagocytosis by providing co-stimulatory signals through neutrophil integrins,43-45 18 
to our knowledge this is the first report on the involvement of neutrophil ICAM-1 in neutrophil 19 
phagocytosis. Of note, ICAM-1 KO neutrophils did exhibit a significant increase in 20 
phagocytosis after LPS stimulation, indicating that as expected ICAM-1-independent 21 
phagocytic pathways such as those involving Mac-1/CR3 or FCγRs are also activated by 22 
LPS.46;47 23 
Phagocytosis is a complex cellular process that is critical for innate immunity.46-49 It is an 24 
adhesion-dependent response with the phagocytic vacuole or phagosome being formed 25 
following association of ligands on the surface of the particle (endogenous constituents of 26 
the target particle or serum-derived opsonins) with receptors on the cell surface of the 27 
phagocyte.46;48 Post-binding of the target, actin-driven intracellular events mediate particle 28 
engulfment.46;48 In addressing the mechanism through which neutrophil ICAM-1 mediates 29 
neutrophil phagocytosis, the functional role of the extracellular and intracellular domains of 30 
ICAM-1 was investigated. An antibody that blocks ICAM-1-integrin interactions had no effect 31 
on neutrophil phagocytosis of zymosan particles. However, as the blocking anti-ICAM-1 mAb 32 
employed has little or no inhibitory effect on ICAM-1 interactions with its other key ligand, 33 
fibrinogen,50-52 the potential involvement of neutrophil ICAM-1 binding to fibrinogen-coated 34 
zymosan particles was a possibility.2;34 The use of a competitive peptide antagonist of ICAM-35 
1-fibrinogen interaction35;53 indicated a modest but significant and specific role for fibrinogen 36 
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in ICAM-1-mediated neutrophil phagocytosis. Additionally, a membrane penetrating peptide 1 
that mimics the intracellular domain of ICAM-1, and has been used to inhibit interactions of 2 
ICAM-1 with cytoplasmic accessory proteins,36;37 inhibited ICAM-1-dependent LPS-3 
stimulated phagocytosis. Collectively, based on our results and published reports we 4 
propose that cell surface neutrophil ICAM-1 can mediate phagocytosis possibly 5 
independently of leukocyte integrins and possibly via interactions of neutrophil ICAM-1 with 6 
fibrinogen-coated particles. This interaction can then trigger ICAM-1-mediated signalling that 7 
supports efficient phagocytosis. The precise details of the latter are unclear and dissecting 8 
the different components was beyond the scope of the present study. However as the 9 
cytoplasmic tyrosine kinase Syk has been linked to phagocytosis by neutrophils and 10 
macrophages,39;40 and is activated by ICAM-1-mediated intracellular signalling in epithelial 11 
cells,38 the role of Syk in ICAM-1-mediated neutrophil phagocytosis was explored. Briefly, 12 
the Syk inhibitor Piceatannol induced a dose-dependent suppression of LPS-induced 13 
neutrophil phagocytosis, with the maximal effect being similar to that seen under conditions 14 
of ICAM-1 deletion.  These results suggest a potential role for Syk in cell autonomous 15 
neutrophil ICAM-1-mediated phagocytosis. Of note, the majority of studies looking at ICAM-1 16 
intracellular signalling have focussed on endothelial ICAM-1 in the context of leukocyte 17 
transmigration.36;54;55 In such studies, clustering and dimerization of endothelial ICAM-1 via 18 
ligation of leukocyte integrins, or cross-linking with antibody coated beads, promote 19 
association of the cytoplasmic domain with adaptor proteins and activation of subsequent 20 
effector pathways. These include modulation of actin polymerisation, the formation of 21 
transmigratory cups that support leukocyte transmigration and endocytosis of anti-ICAM-1 22 
coated microbeads.6;13;56;57 Such events may also be involved in the mechanisms through 23 
which neutrophil ICAM-1 ligation supports particle engulfment. 24 
Antibody-crosslinking of neutrophil ICAM-1 also enhanced LPS-stimulated intracellular ROS 25 
generation. Whilst it is attractive to speculate that this may be associated with pathogen 26 
killing within phagocytic vacuoles, it is also potentially possible that the ROS products 27 
generated support intracellular signalling. Indeed we observed high levels of ROS signal in 28 
cells that had engulfed zymosan (not shown), which may reflect activation of a “pathogen-29 
killing” oxidative burst. In contrast, lower levels of ROS were noted in LPS-stimulated cells, a 30 
response that may reflect activation of signalling pathways. 31 
ROS have been intimately associated with numerous signalling pathways triggered by 32 
ligation of endothelial cell adhesion molecules, including ICAM-1.58 Of relevance, ICAM-1 33 
blockade inhibits production of ROS by neutrophils in response to GM-CSF or PMA,28 and 34 
ICAM-1 cross-linking has been linked to ROS generation and signalling in monocytes,59 35 
indicating a broad role for myeloid cell ICAM-1 signalling as a regulator of superoxide anion 36 
13 
 
generation. Finally, as neutrophils constitutively express the key ICAM-1 ligands, β2 1 
integrins LFA-1 and Mac-1, ICAM-1-mediated neutrophil adhesion/aggregation may trigger 2 
ROS generation in an adhesion-dependent manner, as previously detailed.60   3 
The expression and function of neutrophil ICAM-1 was also investigated in vivo using murine 4 
models of endotoxemia characterised by local neutrophil infiltration and blood neutrophilia. 5 
Within these models, tissue infiltrated and blood vascular neutrophils exhibited enhanced 6 
ICAM-1 levels. Importantly, IL-1β-induced tissue transmigrated neutrophils showed no 7 
ICAM-1 expression indicating that: (i) In line with our in vitro findings, in vivo neutrophil 8 
ICAM-1 induction occurs in a stimulus-specific manner, and (ii) neutrophil transmigration per 9 
se is not sufficient to elicit ICAM-1 expression on neutrophils. Of relevance, human 10 
neutrophils that have migrated through TNF-stimulated cultured endothelial cells exhibit 11 
enhanced ICAM-1 expression though the role of this remains unclear.27 Chimeric mice 12 
deficient in myeloid ICAM-1 indicated no involvement for neutrophil ICAM-1 in neutrophil 13 
tissue infiltration. In contrast to neutrophils, monocyte ICAM-1 has been shown to mediate 14 
adhesion and transendothelial migration, though the associated mechanism remains 15 
unknown.58  16 
Our chimeric mice did however indicate a significant role for neutrophil ICAM-1 in 17 
phagocytosis of zymosan particles in vivo. This was evident with respect to both tissue 18 
infiltrated and blood neutrophils, responses that could collectively reflect events involved in 19 
clearance of both tissue and blood-borne pathogens. With respect to the latter, intravenously 20 
injected zymosan particles were most effectively phagocytosed by neutrophils within the 21 
pulmonary vasculature. The pulmonary vasculature is composed of an extensive network of 22 
small diameter alveolar capillaries through which leukocytes squeeze during normal re-23 
circulation. As a consequence, there is increased transit time of leukocytes through the lungs 24 
resulting in a large pool of slow moving marginating leukocytes.61-64 This low shear 25 
environment provides an ideal setting for bringing marginated neutrophils in close and 26 
prolonged proximity to blood borne pathogens. Our data suggests that filtration of phagocytic 27 
targets from blood, as it passes through the pulmonary vasculature, may be enhanced by 28 
neutrophil-expressed ICAM-1. Hence, whilst it is well accepted that lungs are an important 29 
host defence organ, this may involve pathogen clearance by phagocytes within the interstitial 30 
tissue as well as by circulating neutrophils within the pulmonary vasculature. Of relevance, 31 
whilst ICAM-1 deficient mice are protected from a number of sterile inflammatory conditions 32 
such as diabetic renal injury, radiation induced lung injury and atherosclerosis,65-67 they are 33 
highly susceptible to models of infections.68;69 These phenotypes are considered to be 34 
largely due to profound inhibition of leukocyte extravasation mediated by lack of endothelial 35 
cell ICAM-1. However, our results suggest that neutrophil ICAM-1 deficiency may also 36 
14 
 
contribute to defective pathogen clearance and hence increased mortality in infectious 1 
models. In keeping with these findings is the observation that ICAM-1 KO neutrophils 2 
migrate equivalently to wild type neutrophils into S. pneumoniae infected lungs, but fail to 3 
control the pneumococcal infection.70 This hypothesis is in line with the fact that elevated 4 
neutrophil ICAM-1 has been reported in numerous infectious clinical setting involving 5 
bacterial and viral pathogens,19;20;71 further supporting the concept that elevated neutrophil 6 
ICAM-1 is a physiological component of innate immunity.  7 
The mechanism through which neutrophils are retained in the pulmonary vasculature, most 8 
notably under conditions of infection, remains an elusive issue. Since fibrinogen can mediate 9 
leukocyte-endothelial adhesion,52 we propose that the interaction of neutrophil ICAM-1 with 10 
endothelial cell fibrinogen may provide a mechanism through which neutrophils accumulate 11 
in the pulmonary vascular compartment and contribute to luminal pathogen killing and 12 
clearance. In support of this, analysis of our chimeric mice indicated a higher ratio of WT:KO 13 
neutrophils in the pulmonary vasculature than in the rest of the circulation. Furthermore, 14 
fibrinogen deficient mice exhibit delayed pulmonary injury in response to LPS,72 and whilst 15 
this has been linked to endothelial cell-associated fibrinogen binding to neutrophils via P-16 
selectin and integrins, our data suggest that neutrophil ICAM-1 may also contribute to 17 
pulmonary retention. 18 
In summary, our data provide insight into regulation of expression and function of neutrophil 19 
ICAM-1 in vitro and in vivo, most notably identifying it as a novel regulator of neutrophil 20 
phagocytosis. The findings highlight new avenues of research in host defence and suggest 21 
that induced expression of neutrophil ICAM-1 maybe a means through which pathogen 22 
clearance maybe enhanced in immunocompromised patients.  23 
24 
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Figure Legends 1 
 2 
Figure 1. Murine neutrophils exhibit enhanced ICAM-1 expression in a stimulus-3 
specific manner in vitro.  4 
Whole blood from WT or ICAM-1 KO mice was incubated (4 hrs at 37°C) with IL-1β (50 5 
ng/ml), LTB4 (30 nM), KC (30 nM), fMLP (1 µM), Zymosan (10 µg/ml), LPS (300 ng/ml) or 6 
TNF (100 ng/ml). Post red blood cell (RBC) lysis step, leukocytes were labelled with DAPI, 7 
and fluorescent antibodies against CD45, Ly6G and ICAM-1. Samples were analysed by 8 
flow cytometry. (A) Percentage of ICAM-1 positive neutrophils in WT and ICAM-1 KO 9 
samples. (B) Relative fluorescent intensity (RFI; as compared to isotype control) of 10 
unstimulated and LPS-stimulated WT neutrophils. (C) Representative histogram of ICAM-1 11 
expression on saline or LPS stimulated WT neutrophils, as compared to binding of an 12 
isotype control. (D) Time course of cell surface ICAM-1 expression. (E) Naïve or LPS 13 
stimulated WT neutrophils labelled with fluorescent antibodies against Ly6G and ICAM-1, 14 
and the nuclear marker Draq5. Some samples were permeablised before ICAM-1 labelling to 15 
visualise intracellular stores in addition to surface expression. Cells were imaged by confocal 16 
microscopy and analysed using Imaris imaging software. (F) Q-PCR analysis of ICAM-1 17 
mRNA in saline or LPS stimulated neutrophils. Unstimulated expression levels were 18 
normalised to 1 and LPS stimulated data is shown as fold change compared to unstimulated 19 
samples. (G) Western Blot of ICAM-1 and β-actin loading control in naïve or LPS stimulated 20 
purified neutrophils treated with protease inhibitor at the time of collection. Data are 21 
expressed as mean ± SEM of n=3-27 animals/group. Statistically significant (t-test) 22 
differences between treatment groups are indicated by asterisks: *P<0.05, and ***P<0.001, 23 
and differences between WT and ICAM-1 KO are indicated by hash symbols: #P<0.05, 24 
##P<0.01 and ###P<0.001 25 
 26 
Figure 2. ICAM-1 expression facilitates enhanced neutrophil effector functions.  27 
Whole blood from WT or ICAM-1 KO mice was incubated (4 hrs at 37°C) with IL-1β (50 28 
ng/ml), LTB4 (30 nM), KC (30 nM), fMLP (1 µM), LPS (300 ng/ml) or TNF (100 ng/ml). 29 
Fluorescent ZymTR particles (10 µg/ml) or DHR (1 µM) were added to samples for 15 30 
minutes before RBC lysis and labelling with DAPI and fluorescent antibodies against CD45 31 
and Ly6G. Samples were analysed by flow cytometry. (A) Representative histogram 32 
illustrating the detection of ZymTR associated neutrophils. (B) Percentage of ZymTRpos 33 
neutrophils in unstimulated and LPS-stimulated WT and ICAM-1 KO samples. (C) 34 
Percentage of DHR positive neutrophils, in LPS stimulated as compared to unstimulated 35 
controls was quantified in WT and ICAM-1 KO samples. (D) Frequency of DHR positive 36 
neutrophils within the ICAM-1 positive or negative populations in LPS-stimulated blood. Data 37 
are expressed as mean ± SEM of n=4-24 animals/group. (E) Percentage of DHR positive 38 
neutrophils in WT neutrophils stimulated as shown. Statistically significant (t-test) differences 39 
between treatment groups are indicated by asterisks: **P<0.01, and ***P<0.001, and 40 
differences between WT and ICAM-1 KO are indicated by hash symbols: #P<0.05, 41 
###P<0.001. 42 
 43 
Figure 3. Mechanism of neutrophil ICAM-1-mediated enhanced effector functions.  44 
22 
 
Whole blood from WT or ICAM-1 KO mice was incubated with LPS (300 ng/ml, 4 hrs at 1 
37°C). In some experiments, samples were treated with inhibitors as detailed, prior to 2 
addition of ZymTR for a further 15 minutes. Unless indicated, results are presented as 3 
percentage inhibition of LPS-stimulated ZymTR phagocytosis. (A) LPS-stimulated samples 4 
were treated with blocking antibodies against ICAM-1 (clone YN1/1.7.4) or Mac-1 (clone 5 
M1/70) (both at 10 µg/ml for 15 minutes). (B) LPS-stimulated samples were treated with 6 
fibrinogen-γ-117-113 peptide to block ICAM-1-fibrinogen interaction (300 µM for 30 minutes). 7 
(C) LPS-stimulated samples were incubated with a membrane penetrating peptide consisting 8 
of 13 C-terminal amino acids of ICAM-1 that inhibits ICAM-1-mediated intracellular signalling 9 
(200 µg/ml for 120 minutes at 37°C). (D) LPS-stimulated WT or ICAM-1 KO samples were 10 
treated with the Syk inhibitor Piceatannol (30 minutes). (E) Percentage of DHR positive 11 
neutrophils in saline or LPS-stimulated samples following antibody cross-linking of ICAM-1 12 
using rat-anti-ICAM-1 primary antibody (10 µg/ml, 15 minutes) and anti-rat secondary 13 
antibody (10 µg/ml, 15 minutes). Data are expressed as mean ± SEM of n=8-15 14 
animals/group. Statistically significant (t-test) differences between control and treatment 15 
groups are indicated by asterisks: *P<0.05, **P<0.01, and ***P<0.001, and differences 16 
between WT and ICAM-1 KO treatments are indicated by hash symbols: ###P<0.001. 17 
 18 
Figure 4. ICAM-1 is expressed on LPS-stimulated neutrophils in vivo.  19 
WT mice were injected with saline, LPS (300 ng intrascrotal route [i.s]. or 1000 ng 20 
intraperitoneal route [i.p.]) or IL-1β (50 ng i.p and i.s.). After a 4 hour in vivo test period, 21 
blood, lungs, peritoneal lavage and cremaster muscles were collected. Cremaster muscles 22 
were fixed and permeablised and labelled with fluorescent antibodies against PECAM-1, the 23 
intracellular neutrophil marker S100a9 and ICAM-1 or an isotype control. Tissues were 24 
imaged by confocal microscopy and analysed using Imaris. Following RBC lysis and 25 
enzymatic digestion of lung tissues, leukocytes from the blood, lung tissue digest and 26 
peritoneal lavage were labelled with DAPI and fluorescent antibodies against CD45, Ly6G 27 
and ICAM-1, or an isotype control. (A) Representative images of unstimulated and 28 
stimulated cremaster muscles. (B and C) Quantification of extravasated neutrophils in saline 29 
and stimulated inflamed sites. (D) Representative images of ICAM-1 expression on 30 
extravasated neutrophils in LPS- and IL-β-stimulated cremaster muscles. (E and F) 31 
Quantification of ICAM-1 expression on extravasated neutrophils in inflamed tissues. (G) 32 
Percentage of Ly6G positive neutrophils amongst CD45 positive leukocytes in blood and 33 
digested lung tissue samples as quantified by flow cytometry. (H) Percentage of ICAM-1 34 
positive neutrophils in blood of saline, IL-1β- and LPS-stimulated animals. Data are 35 
expressed as mean ± SEM of n=3-10 animals/group. Statistically significant (t-test or 36 
ANOVA) differences between stimulated and unstimulated treatment groups are indicated by 37 
asterisks: *P<0.05, **P<0.01, ***P<0.001. Differences between stimuli are indicated by hash 38 
symbols: ##P<0.01, ###P<0.001. 39 
 40 
Figure 5. Neutrophil ICAM-1 does not support neutrophil transmigration in vivo.  41 
Extravasation of WT or ICAM-1 KO neutrophils was quantified using chimeric WT mice with 42 
a mix of WT-LysM-GFP and ICAM-1 KO (GFP negative) neutrophils. Chimeric mice were 43 
stimulated with LPS (1000 ng i.s. or i.p.) and cremaster muscle tissues and peritoneal lavage 44 
fluid was collected and labelled with fluorescent antibodies against PECAM-1 and S100a9 45 
(cremasters), or CD45 and Ly6G (lavage). (A) Representative image of extravasated WT 46 
23 
 
and ICAM-1 KO neutrophils in LPS-stimulated cremaster muscles. (B and C) Quantification 1 
of extravasated WT-LysM-GFP and ICAM-1 KO neutrophils in saline and/or LPS-stimulated 2 
inflamed tissues. Values are normalised to the WT:KO ratio in the peripheral blood of each 3 
animal. Data are expressed as mean ± SEM of n=6-10 animals/group. Statistically significant 4 
(t-test or ANOVA) differences between stimulated and unstimulated treatment groups are 5 
indicated by asterisks: *P<0.05, **P<0.01. 6 
 7 
Figure 6. ICAM-1 facilitates neutrophil phagocytosis in vivo.  8 
Chimeric WT mice with a mix of WT-LysM-GFP and ICAM-1 KO (GFP negative) neutrophils 9 
were injected with LPS (1000 ng i.p.). After 4 hrs ZymTR was injected i.p. (10 µg) or i.v. (100 10 
µg) 15 minutes before collection of blood, lung tissues and peritoneal lavage. Following RBC 11 
lysis and enzymatic digestion of lung tissues, cells were labelled with DAPI and fluorescent 12 
antibodies against CD45 and Ly6G, and analysed by flow cytometry. (A) Percentage of 13 
ZymTR associated WT-LysM-GFP or ICAM-1 KO neutrophils in peritoneal lavage. (B) 14 
Percentage of ZymTR associated WT-LysM-GFP or ICAM-1 KO neutrophils in blood and 15 
enzymatically digested lung tissues.  (C) Total number of ZymTRpos WT-LysM-GFP or ICAM-16 
1 KO neutrophils in the lungs of saline or LPS stimulated animals. Values are normalised to 17 
the WT:KO ratio in the tissue of each animal. (D) Representative images showing 18 
neutrophils and ZymTR particles in LPS stimulated pulmonary or cremasteric circulation 15 19 
minutes after i.v. injection of ZymTR.  Data are expressed as mean ± SEM of n=6-10 20 
animals/group. Statistically significant (t-test) differences between treatment groups are 21 
indicated by asterisks: *P<0.05.  Differences between WT-LysM-GFP and ICAM-1 KO are 22 
indicated by hash symbols: ##P<0.01, ###P<0.001. 23 
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Supplementary Materials and Methods  1 
Animals 2 
Male WT C57BL/6 mice were purchased from Charles River Laboratories. ICAM-1 KO 3 
animals were obtained from Drs Britta Engelhardt and Urban Deutsch with permission of Dr 4 
Art Beaudet1.  Heterozygous mice in which the gene for eGFP has been knocked-in to the 5 
lysozyme M (LysM) locus (LysM-eGFP-ki),2 resulting in the exhibition of eGFP high levels of 6 
eGFP in neutrophils and to a lesser extent monocytes were used to distinguish WT and 7 
ICAM-1 KO PMN in mixed populations. These mice are now referred to as WT-LysM-eGFP 8 
to indicate that they contain functional ICAM-1 genes. All genetically modified animals were 9 
on a C57BL/6 background. Animals were housed in individually ventilated cages and 10 
facilities were regularly monitored for health status and infections. Experiments were 11 
performed under the UK legislation for the protection of animals, and at the end of all in vivo 12 
procedures animals were humanely killed by cervical dislocation in accordance with UK 13 
Home Office regulations.  14 
 15 
Reagents & antibodies  16 
IL-1β, LPS, LTB4, fMLP, DAPI and EZ-view Protein G affinity gel were purchased from 17 
Sigma-Aldrich. Dihydrorhodamine-123 (DHR), AlexaFluor antibody conjugation kits and 18 
Zymosan-Texas-Red (ZymTR) were purchased from Invitrogen. Antibodies were purchased 19 
from eBioscience, Biolegend, Abcam, Pharmingen, Santa Cruz, Sigma-Aldrich or were 20 
provided by Research Cell Services, Cancer Research UK London Research Institute: anti-21 
CD45 (clone 30-F11), anti-Ly6G (clone 1A8), anti-ICAM-1 (clone YN1/1.7.4), anti-ICAM-1 22 
(clone H-108), anti-β-actin (cloneAC-74), anti-PECAM-1 (clone C390), anti-MAC-1 (clone 23 
M1/70), anti-S100a9 (clone 2B10), rat IgG2b and IgG2a isotype controls. For confocal 24 
imaging or flow cytometry primary antibodies were either directly conjugated commercially 25 
(PE, FITC, PECy7, Pacific Blue, Alexa-488, Alexa-555, Alexa-633, Alexa-700) or labelled 26 
with Invitrogen AlexaFluor antibody conjugation kits in house. ICAM-1/fibrinogen binding 27 
inhibitor peptide was synthesised by Bachem. ICAM-1 signalling inhibitor peptide was 28 
synthesized by Cambridge Peptides. Qiagen RNeasy Microkit iScript cDNA synthesis kit and 29 
Sybr green supermix were purchased from (Biorad). ICAM-1 and GAPDH primers were 30 
purchased from Integrated DNA Technologies. HALTTM protease and phosphotase inhibitor 31 
cocktail was purchased from Pierce.  32 
 33 
Generation of chimeric mice 34 
Generation bone marrow chimeric mice was based on published methods 3. Bone marrow 35 
was isolated from the tibias of WT, ICAM-1 KO or WT-LysM-eGFP mice under sterile 36 
conditions and suspended in sterile PBS at 5x106/ml. WT recipient mice were lethally 37 
irradiated with two doses of 5 Gy, 4 hours apart using a RadSource-2000 irradiator. After the 38 
second irradiation mice were given an intravenous (i.v.) injection of 1x106 bone marrow cells 39 
in 200 µl PBS. After irradiation and bone marrow transfer animals were maintained in 40 
individually ventilated cages and given acidified (pH 2.6) water and Baytril for 4-6 weeks 41 
before use. Chimeric mice had an average ratio of 60:40 WT:KO neutrophils in the 42 
circulation, and data from each animal was normalised to the individual ratio (see also 43 
Supplementary Figure 1). 44 
 45 
In vivo inflammatory responses 46 
31 
 
Animals were sedated via intramuscular (i.m.) injection of 1 ml/kg anaesthetic (40 mg/kg 1 
Ketamine and 2 mg/kg Xylazine in saline) and given intrascrotal (300 µl i.s.) or 2 
intraperitoneal (500 µl i.p.) injections of LPS (300ng or 1000 ng) or IL-1β (50 ng), with an 3 
incubation period of 4 hrs. In some cases fluorescent Zymosan-Texas-Red (ZymTR) was 4 
given i.p. (10 µg) or i.v. (100 µg) 15 minutes prior to collection of blood, lungs, peritoneal 5 
lavage or cremasters. In some cases i.s. injections of inflammatory mediators were co-6 
administered with fluorescent anti-PECAM-1 mAb (4 µg) to label the cremasteric 7 
vasculature. Animals were sedated (125 mg/kg Ketamine, 12.5 mg/kg Xylazine) i.p. or killed 8 
by cervical dislocation. Blood was collected into heparinised PBS via cardiac puncture or 9 
cannulation of the abdominal vena cava. To collect the lungs the chest was opened and a 10 
clamp was placed on the thoracic vena cava and aorta just above the diaphragm. The 11 
pulmonary vasculature of the lungs was then perfused with 10 ml of PBS containing heparin 12 
and EDTA by direct injection into the right ventricle, and collection via a cannula inserted into 13 
the left ventricle. Vascular wash out was confirmed by whitening of the lung tissue, which 14 
was then excised, finely chopped, and digested for 30 minutes in 1 ml PBS with collagenase 15 
and DNAse (500 U and 200 U respectively), and passed through a 40 µm cell sieve. The 16 
peritoneal cavity was lavaged with 6 ml PBS/EDTA and cells we counted using a 17 
haemocytometer and analysed by flow cytometry to assess extravasation and phagocytosis 18 
efficiency. Cremasters were also collected, fixed, permeablised and immunofluorescently 19 
labelled. 20 
 21 
In vitro stimulation  22 
Neutrophil responses to various in vitro inflammatory stimuli were analysed. Whole blood 23 
was collected into heparinised PBS from naïve mice via cannulation of the vena cava and 24 
treated with LPS (30 or 300 ng/ml), IL-1β (100 ng/ml), LTB4 (30 nM), KC (30 nM) or fMLP (1 25 
µM), TNFα (100 ng/ml) or Zymosan (10 µg/ml) for up to 4 hrs at 37˚C. Phagocytosis was 26 
quantified by addition of 10 µg/ml fluorescent ZymTR to whole or lysed blood, and incubation 27 
for 15 minutes at 37˚C (approximate ratio of 10:1 ZymTR:neutrophils). As has been 28 
previously reported4 blood from naïve ICAM-1 KO  mice exhibited significantly elevated 29 
numbers of neutrophils (WT 0.53±0.06, ICAM-1 KO 0.73±0.07 million/ml, P<0.05*), but the 30 
high ratio of ZymTR:neutrophils would negate this difference. ROS generation was 31 
quantified using the fluorescent intracellular probe DHR added to whole blood 15 minutes 32 
prior to lysis and analysis (1 µM). In some cases function blocking antibodies or the inhibitor 33 
Piceatannol was added prior to ZymTR. In some cases a 17 amino acid peptide from the 34 
gamma domain of fibrinogen that binds to domain 1 of ICAM-1 and competitively inhibits 35 
ICAM-1/fibrinogen interactions was used (sequence: NNQKIVNLKEKVAQLEA).5 Whole 36 
blood was stimulated with 300 ng/ml LPS for 3 hrs before addition of 300 µM peptide for a 37 
further 30 minutes, and ZymTR (10 µg/ml) for a further 15 minutes before lysis and analysis 38 
by flow cytometry. In some cases a biotinylated peptide comprised of a 16 amino acid cell 39 
membrane penetrating sequence followed by 13 C-terminal amino acids of mouse ICAM-1 40 
was used to inhibit intracellular signalling of ICAM-1: (sequence Bio-41 
RQIKIWFQNRRMKWKK-QRKIRIYKLQKAQ).6 Whole blood was stimulated with 300 ng/ml 42 
LPS for 3 hrs before addition of 200 µg/ml inhibitor for a further 2 hrs, and ZymTR (10 µg/ml) 43 
for a further 15 minutes before lysis and analysis by flow cytometry. 44 
 45 
Flow Cytometry 46 
Whole blood from in vitro stimulations, or whole blood, peritoneal lavage or digested lung 47 
tissue from in vivo experiments, were lysed with ACK lysis buffer as required (150 mM 48 
32 
 
NH4Cl, 1 mM KHCO3, 0.1 mM EDTA), and stained with fluorescently conjugated antibodies 1 
against CD45, Ly6G, ICAM-1, CD18, or the appropriate isotype control antibodies (0.2 – 2 2 
µg/ml, various fluorochromes). Leukocytes were identified by FSC and SSC characteristics 3 
and CD45 positive staining, dead cells were excluded by DAPI staining, and neutrophils 4 
were identified based on Ly6G mAb staining or LysM-eGFP positivity. ICAM-1 was labelled 5 
with an APC conjugated antibody and positive neutrophils were gated after determining the 6 
level of background fluorescence in the ICAM-1 KO or isotype control stained samples using 7 
633/670 nm excitation/emission. ZymTR associated neutrophils from in vitro or in vivo 8 
experiments were identified by 560/585 nm excitation/emission. ROS generation was 9 
quantified by loading cells with 1 µM DHR for 15 minutes at 37˚C, DHR fluorescence was 10 
quantified by flow cytometry at 488/530 nm excitation/emission. DHR positive neutrophils 11 
were identified as cells with a higher DHR signal than an unstimulated, but DHR loaded, 12 
control. Samples were analysed using a BD LSR-Fortessa (BD Biosciences) and FloJo 13 
analysis software (Treestar). In some studies the intracellular or surface bound location of 14 
neutrophil associated ZymTR was analysed using the ImageStreamX Mk II imaging 15 
cytometer, which combines fluorescence microscopy with high-throughput flow cytometry. 16 
Neutrophils were identified as being positive for CD45 and Ly6G labelling, and a mask was 17 
applied to the Ly6G positive regions of ZymTR positive neutrophil events. The frequency at 18 
which the ZymTR signal fell within the Ly6G mask (intracellular) or outside the Ly6G mask 19 
(surface bound) was quantified.  20 
 21 
Confocal microscopy 22 
Cremasters were fixed with 4% PFA, blocked with 20 % FCS and permeablised with 0.5 % 23 
Triton-X-100. Cremasters were incubated with fluorescent anti-PECAM-1, anti-S100a9, anti-24 
ICAM-1 or isotype control. Lung tissues from WT-LysM-GFP mice were incubated with 5 25 
µg/ml Lectin IB4-Alexa-647 for 2 hours before the surface of the lungs was imaged. Tissues, 26 
or isolated neutrophils, were viewed using a Leica SP5 confocal microscope incorporating a 27 
20× water-dipping objective (NA 1.0). For analysis of LPS and IL-1β stimulated extravasation 28 
Z-stack images of 3-5 post-capillary venules with 20–45 µm diameters per cremaster were 29 
captured, and extravasated neutrophils were quantified (3-4 mice per group). ICAM-1 30 
expression on extravasated neutrophils was carried out by building an isosurfaces on the 31 
S100a9 channel, and quantifying the ICAM-1 signal within this surface. Image analysis 32 
carried out using Imaris (Bitplane) 3D analysis software or Leica LASF-Lite software.  33 
 34 
Quantitative RT-PCR 35 
Neutrophils were purified from blood or lung digests by flow sorting for analysis of ICAM-1 36 
mRNA levels using BD FACS-ARIA (BD Biosciences). Leukocytes were identified by FSC 37 
and SSC characteristics and CD45 positive staining, dead cells were excluded by DAPI 38 
staining, and neutrophils were identified based on Ly6G positivity. Purified samples were 39 
84.9 % neutrophils.  Following purification total RNA was purified from cells using the Qiagen 40 
RNeasy Microkit as described by the manufacturers. cDNA was synthesized from 10 ng total 41 
RNA using the iScript cDNA synthesis kit. Quantitative Real Time PCR was performed on an 42 
ABI7900HT real time PCR machine and reactions were prepared using the iQ Sybr green 43 
supermix.  44 
ICAM - Forwards: GACAGTACTGTACCACTCTC, Reverse:CCTGAGCCTTCTGTAACTTG,  45 
GAPDH - Forwards:TCGTGGATCTGACGTGCCGCCTG, Reverse:CACCACCCTGTTGCTGTAGCCGTA. 46 
 47 
Western Blot 48 
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WT blood was stimulated with 1000 ng/ml LPS or saline for 4 hours. Ly6Gpos Neutrophils 1 
were purified from blood or lung digests by flow sorting using BD FACS-ARIA (BD 2 
Biosciences), and pellets re-suspended in RIPA buffer with HaltTM protease inhibitor cocktail. 3 
Cells were run on a 10% gel and transferred by semi-dry transfer. ICAM-1 expression and β-4 
actin loading control were detected by anti-ICAM-1 (1:50, clone H-108), anti-β-actin (1:2000, 5 
clone AC-74).  6 
 7 
Statistical analysis 8 
Results are presented as mean ± s.e.m. Statistical significance was assessed by the 9 
Student T-test or by one-way analysis of variance (ANOVA) with the Newman-Keuls multiple 10 
comparison test. Where T-tests were used a paired T-test was used to compare samples 11 
from the same animal which had been subjected to different treatments (e.g. unstimulated 12 
and LPS stimulated blood), while comparison of samples from different animals were 13 
analysed using an unpaired test.  P values below 0.05 were considered significant. 14 
 15 
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 1 
Supplementary Figure 1. WT and ICAM-1 KO neutrophils in chimeric mice.  2 
A mixture of WT-LysM-eGFP and ICAM-1 KO bone marrow was injected intravenously (i.v.) 3 
to irradiated WT mice to create chimeric mice that expressed ICAM-1 on the vasculature 4 
with ICAM-1 KO or WT-LysM-GFP leukocytes. (A) There was a 60:40 WT:ICAM-1 KO 5 
neutrophils in the blood. (B) In digested lung tissues there was a slight increase in the 6 
proportion of WT neutrophils as compared to the blood (from 60.1±3.8% to 68.7±3.6%), 7 
indicating a possible preferential retention of WT cells in the vasculature of the lung. Data 8 
are expressed as mean ± SEM of n=8-12 animals/group. Statistically significant (t-test) 9 
differences are indicated by asterisks: *P<0.05. 10 
